The British Nuclear Medicine Society has worked with the Royal College of Radiologists and the UK Radiopharmacy Group to produce practical guidance to help nuclear medicine teams plan radioisotope work in case of a no-deal Brexit.
Practical advice for radiopharmacy and nuclear medicine services in the event of a no-deal Brexit outlines industry updates on supplier preparedness for tracer and therapeutic radioisotope supply in the event of no-deal, and urges clinicians to liaise directly with their suppliers for information on individual products.
It contains advice to help services produce individual risk assessments, emphasising the importance of communication and supply networking between hospitals.
The guidance contains practical advice on procurement changes and considerations for workload planning and case prioritisation depending on supply alterations.
The planning document also lists product alternatives and substitutions for particular imaging procedures, as well as key considerations for oncology teams faced with irregular supply.
The House of Commons Health and Social Care made a call for evidence concerning the effect a "hard Brexit" will have on the patient care.
BNMS members were called to put forward their comments and a report was submitted as evidence from the BNMS. This report was created with contributions from BNMS members and stakeholders.
Hard Brexit Impact Report - 15th October 2018 (without appendices)